New strategies for the treatment of metastatic bone disease.
The introduction of bisphosphonates represents an important advance in the care of patients with metastatic bone disease. Nonetheless, we remain unable to prevent metastatic bone destruction. This review will discuss several novel therapies, including inhibitors of receptor activator of nuclear factor-kappabeta, c-Src, mammalian target of rapamycin, cathepsin K, and alpha(5)beta(3) integrins, which could improve our control over this devastating complication.
Pearse
Roger N
RN
Department of Medicine, Division of Hematology/Medical Oncology, Cornell University, 1300 York Avenue, New York, NY 10065, USA. RNP2001@med.cornell.edu
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D016723:Bone Remodeling / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D056657:Cathepsin K; D002403:Cathepsins / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D039001:Integrin alpha Chains; D039641:Integrin beta Chains; D020123:Sirolimus / Q000627:therapeutic use
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D015507:Drugs, Investigational; D039001:Integrin alpha Chains; D039641:Integrin beta Chains; D002403:Cathepsins; C534130:CTSK protein, human; D056657:Cathepsin K; D020123:Sirolimus